Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PDE5A | O76074 | 1/20 | 0.31 |
| ▸ | IDH1 | O75874 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.30 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.30 |
| ▸ | DYRK2 | Q92630 | 2/20 | 0.30 |
| ▸ | CLK1 | P49759 | 2/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.30 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.30 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.30 |
| ▸ | CLK2 | P49760 | 1/20 | 0.30 |
| ▸ | CLK3 | P49761 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3522822 | 0.86 | ALDH1A1 (0.39) | BRD4CREBBPTP53MAPTSMN1; SMN2 | |
| SCHEMBL11784017 | 0.82 | BRD4 (0.37) | BRD4CREBBPMAPT | |
| SCHEMBL11826346 | 0.81 | MAPT (0.37) | TP53MAPTSMN1; SMN2CXCR3 | |
| SCHEMBL11815335 | 0.80 | BRD4 (0.37) | BRD4CREBBPTP53MAPTSMN1; SMN2 | |
| SCHEMBL3527482 | 0.78 | ALDH1A1 (0.44) | TP53MAPTSMN1; SMN2 | |
| SCHEMBL11813360 | 0.77 | THRB (0.38) | BRD4TP53MAPTSMN1; SMN2 | |
| SCHEMBL11816311 | 0.76 | MAPT (0.35) | TP53MAPTSMN1; SMN2CXCR3 | |
| SCHEMBL11818360 | 0.76 | BRD4 (0.37) | BRD4CREBBPMAPTSMN1; SMN2DYRK1A | |
| SCHEMBL3525026 | 0.75 | ALDH1A1 (0.49) | TP53MAPTSMN1; SMN2 | |
| SCHEMBL3522871 | 0.75 | ALDH1A1 (0.49) | TP53MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7652006-B2 | For therapy and prophylaxis of neuronal loss associated with stroke, global and focal ischemia, CNS trauma, hypoglycemia and surgery, for ameliorating neurodegenerative diseases | EURO-CELTIQUE S.A. (LU) | 2010-01-26 | — | — | US | disclosed |
| US-20040162299-A1 | Substituted quinazolines and analogs and the use thereof | EURO-CELTIQUE, S.A. | 2004-08-19 | — | — | US | disclosed |
| US-6765006-B2 | ANTAGONISTS OF AMINO-3-HYDROXY-5-METHYLISOXAZOLE-4-PROPIONIC ACID (AMPA) IONOTROPIC RECEPTORS; NEURODEGENERATIVE, ALZHEIMER'S, AND HUNTINGTON'S DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; SCHIZOPHRENIA, EXCITATORY AMINO ACID DEFICIENCY | EURO-CELTIQUE S.A. (LU) | 2004-07-20 | — | — | US | disclosed |
| EP-1066039-A4 | SUBSTITUTED QUINAZOLINES AND ANALOGS AND THE USE THEREOF | COCENSYS INC (US) | 2003-02-26 | — | — | EP | disclosed |
| US-20030033089-A1 | Substituted quinazolines and analogs and the use thereof | EURO-CELTIQUE S.A. | 2003-02-13 | — | — | US | disclosed |
| US-6465472-B1 | SUCH AS 1-(2-DIETHYLAMINOETHYL)-6,7-METHYLENEDIOXY-4-(3,4-METHYLENE -DIOXYPHENYL)QUINAZOLIN-2(1H)-ONE; AMPA IONOTROPIC RECEPTOR ANTAGONISTS; ANTICONVULSANTS, COGNITIVE ENHANCERS, PREVENTION OF NEURODEGENERATION | EURO-CELTIQUE S.A. (LU) | 2002-10-15 | — | — | US | disclosed |
| EP-1066039-A1 | SUBSTITUTED QUINAZOLINES AND ANALOGS AND THE USE THEREOF | Cocensys, Inc. (US) | 2001-01-10 | — | — | EP | disclosed |
| WO-1999044612-A1 | SUBSTITUTED QUINAZOLINES AND ANALOGS AND THE USE THEREOF | COCENSYS, INC. (US) | 1999-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162299-A1 | Substituted quinazolines and analogs and the use thereof | CHRNA7, CHRNA2, CHRNA10 | BRD4 2086/4885CREBBP 711/4885TP53 2202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.